Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.04
-0.11 (-1.79%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $5.02M in the quarter ending March 31, 2026, with 46.06% growth. This brings the company's revenue in the last twelve months to $37.16M, up 417.63% year-over-year. In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth.
Revenue (ttm)
$37.16M
Revenue Growth
+417.63%
P/S Ratio
2.79
Revenue / Employee
$488,961
Employees
76
Market Cap
103.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.94M |
| Cibus | 3.64M |
| Cardiff Oncology | 525.00K |
VRCA News
- 1 day ago - Verrica Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 days ago - Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright - TheFly
- 17 days ago - Verrica Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 23 days ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 24 days ago - Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c) - TheFly
- 24 days ago - Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 24 days ago - Verrica Pharmaceuticals Earnings release: Q1 2026 - Filings